PHILADELPHIA, Sept. 5, 2013 /PRNewswire via COMTEX/ -- Echo Therapeutics, Inc.
(Nasdaq: ECTE), a medical device company developing its needle-free SymphonyŽ
CGM System as a non-invasive, wireless, continuous glucose monitoring system,
announced that the independent members of the Board of Directors and Mr. Robert
F. Doman, the Executive Chairman and Interim Chief Executive Officer, today sent
a letter to its shareholder, Platinum-Montaur Life Sciences, LLC, in response to
an August 30, 2013 public communication made by Platinum-Montaur and its
affiliated funds. In addition, Echo has communicated with Platinum-Montaur to
discuss the matters raised in the August 30, 2013 communication. The Company and
Platinum-Montaur have scheduled a meeting for next week.
As Echo has previously announced, it continues to consider and seek to enter
into collaborations or licenses regarding the future development and
distribution of its products and remains willing to enter into discussions
regarding potential collaborations or licenses.
slam dunk to $5 once they get this crap sorted out IMO!!!!!!!!!!!!
ONLY MY OPINION!!!!!!!!!!!
Frustrating with all this drama.
Do your research! Play the TA. All posts are my opinion.
